ft-1

FTI-2148 is an inhibitor of RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) (IC50s: 1.4 nM and 1.7 μM, respectively).

FTI-2148 diTFA is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 1.4 nM and 1.7 μM, respectively.

Notoginsenoside Ft1 是一种植物分离的三七皂苷，具有刺激血管生成的作用。

FT-1101 is an orally bioavailable, potent and selective BET inhibitor. FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.

CFT-1297为BETPROTAC类的降解剂，具备降解BRD4的能力。

FT-1518 是一种可口服且具有选择和高效性的 mTORC1 和 mTORC2 抑制剂，具有抗癌抗肿瘤活性，可用于研究癌症。

FT-1101 is an oral bioavailable, effective and selective BET inhibitor.

FT113 是口服具有活力的脂肪酸合酶抑制剂，对全长重组人 FASN 酶的 IC50=213 nM。在 BT474 细胞中，它抑制 FASN 的特性，IC50=90 nM。它具有抗增殖作用，在体内和体外实验中，都具有抗癌作用。

CFT1946是一种双功能降解激活化合物 （BiDAC）降解剂，包含靶向与 cereblon 配体连接的 BRAF 激酶结构域配体。CFT1946 能够降解 BRAF V600E（I 类）、G469A（II 类）、G466V（III 类）突变和 p61-BRAFV600E 剪接变体，同时对蛋白质组（包括 WT BRAF 和 CRAF）保持极好的选择性。

Nepicastat hydrochloride monohydrate is an inhibitor of dopamine beta-hydroxylase, an enzyme that catalyzes the conversion of dopamine to norepinephrine.

(Rac)-Etavopivat((Rac)-FT-4202) 是Etavopivat 异构体。Etavopivat 是一种具有口服活性的的红细胞丙酮酸激酶-R (PKR) 激活剂，可以用于镰状细胞病和其他血红蛋白疾病研究。

FGTI-2734 是 有效的RAS C-末端法尼基转移酶 (FT) 和香叶烯基转移酶-1 (GGT-1) 抑制剂，IC50s 分别为 250 nM 和 520 nM。 它可以阻断 KRAS 的膜定位，从而解决 KRAS 耐药性问题，并抑制突变的 KRAS 胰腺肿瘤。

Borneol 7-O-[beta-D-apiofuranosyl-(1->6)]-beta-D-glucopyranoside is a natural product from Radix ophiopogonis.

Olutasidenib (FT-2102) 是一种可透过血脑屏障的、具有口服活性的、突变型异柠檬酸脱氢酶(IDH)1的选择性有效抑制剂，对IDH1- R132H 和 IDH1- R132C 的IC50分别为 21.2 nM 和 114 nM，可用于急性髓性白血病或骨髓增生异常综合征的研究。

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.